2nd Annual Best Practice in Clinical Site Selection &amp.

2nd Annual Best Practice in Clinical Site Selection & Management 2-4 March, 2009, Cascais , Portugal. This event will show a fresh and primary perspective on improving the functionality of clinical trials. It will be looking at improving efficiency when choosing scientific sites and managing an individual site’s performance. This event will be unique because other events are all looking at the same broad, big picture, general, general, top-down, method of improving clinical functionality.The info demonstrated that usage of XIENCE V resulted in significantly lower clinical event rates carrying out a stent procedure. In the pooled evaluation, XIENCE V demonstrated a 36 % decrease in the risk of main adverse cardiac occasions in comparison to TAXUS . MACE is an important composite clinical way of measuring efficacy and protection outcomes for patients, defined as cardiac death, heart attack , or retreatment of a lesion . ‘XIENCE V consistently demonstrated low adverse cardiac event rates in trial after trial,’ said Dr. Kereiakes. ‘The SPIRIT II, III, IV, and COMPARE pooled evaluation shows that XIENCE V reduced the occurrence of adverse occasions compared to individuals treated with the TAXUS stent. The low event rates demonstrated by XIENCE V in these trials are specially impressive provided the complexity of patients in the SPIRIT IV and COMPARE trials and concur that the results noticed with XIENCE V in previously randomized medical trials are in keeping with scientific practice.’ Related StoriesWyss Institute, UMass team up to develop drug-device combination for treating blood clots in stroke patientsLEADERS FREE clinical trial demonstrates excellent basic safety, efficacy for BioFreedom compared with bare-metal stentDAPT Study shows dual antiplatelet therapy reduces bleeding-related mortalityXIENCE V Displays Positive Results in Data Provided at ACC In addition to the 36 % decrease in the chance of overall MACE compared to TAXUS, data also were provided at ACC from the pooled evaluation that demonstrated the following for XIENCE V: A 47 % decrease in the risk of heart attack A 40 % reduction in the chance of cardiac loss of life or heart attack A 70 % decrease in the chance of stent thrombosis, defined as definite or probable according to ARC ‘The pooled evaluation of the SPIRIT II, III, IV and Compare and contrast trials further supports the strong body of scientific evidence that has made XIENCE V a respected medication eluting stent technology for sufferers and physicians,’ said Charles A.